|Dr. Michael G. Kauffman M.D., Ph.D.||Co-Founder, Chief Exec. Officer and Director||773.46k||N/A||54|
|Dr. Sharon Shacham Ph.D., M.B.A.||Co-Founder, Co-Chairman of Scientific Advisory Board, Pres and Chief Scientific Officer||592.26k||N/A||47|
|Mr. Justin A. Renz CPA, MST, MBA||Advisor||485.36k||N/A||45|
|Dr. Mansoor Raza Mirza M.D.||Clinical Consultant, Director and Member of Scientific Advisory Board||254.38k||N/A||56|
|Mr. Michael J. Todisco CPA||Acting Principal Financial and Accounting Officer||N/A||N/A||52|
Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor, which is in Phase IIb clinical trial for patients with heavily pretreated multiple myeloma; Phase Ib/II clinical study in combination with backbone treatments for relapsed/refractory multiple myeloma; Phase II/III clinical trial for patients with relapsed and/or refractory multiple myeloma; Phase II clinical study to treat acute myeloid leukemia; Phase IIb clinical trial for patients with diffuse large B-cell lymphoma; and Phase II/III clinical trial to treat liposarcoma. The company is also developing KPT-8602 that is in Phase I/II study for patients with relapsed/refractory multiple myeloma; KPT-9274, which is in Phase I clinical trial for patients with advanced solid malignancies or non-Hodgkins lymphoma; KPT-335, which is in Phase I clinical trial for the treatment of viral indications; and KPT-350 that is in preclinical stage to treat neurological disorders, and inflammatory and autoimmune diseases. Karyopharm Therapeutics Inc. was founded in 2008 and is headquartered in Newton, Massachusetts.
Karyopharm Therapeutics Inc.’s ISS Governance QualityScore as of August 1, 2017 is 8. The pillar scores are Audit: 2; Board: 5; Shareholder Rights: 8; Compensation: 8.